Exploring the Influence of Concurrent Nutritional Therapy on Children with Spinal Muscular Atrophy Receiving Nusinersen Treatment

被引:0
|
作者
Pinar, Eymen [1 ]
Ayvaz, Bilal Berke [1 ]
Akkus, Erkan [2 ]
Ulkersoy, Ipek [2 ]
Dilek, Tugce Damla [3 ]
Zindar, Yilmaz [3 ]
Ulug, Fitnat [3 ]
Guzeler, Aysel [3 ]
Kilic, Huseyin [3 ]
Guler, Serhat [3 ]
Beser, Omer Faruk [2 ]
Saltik, Sema [3 ]
Cullu Cokugras, Fugen [2 ]
机构
[1] Istanbul Univ, Cerrahpasa Med Fac, Dept Pediat, Pediat, TR-34000 Istanbul, Turkiye
[2] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Pediat, Div Pediat Gastroenterel Hepatol & Nutr, TR-23119 Istanbul, Turkiye
[3] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Pediat, Div Pediat Neurol, TR-34000 Istanbul, Turkiye
来源
CHILDREN-BASEL | 2024年 / 11卷 / 08期
关键词
motor functions; malnutrition; screening tools; nutritional intervention; PYMS; STAMP; 3 SCREENING TOOLS; SHAM CONTROL; MALNUTRITION; MANAGEMENT; RISK; DIAGNOSIS;
D O I
10.3390/children11080886
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background This study examines spinal muscular atrophy (SMA), a neuromuscular disease associated with malnutrition. Our goals are to assess how effectively screening tools can detect malnutrition and evaluate the impact of nutritional interventions on neurological outcomes, particularly motor functions. Methods Thirty-seven genetically diagnosed SMA patients (types 1, 2, and 3) under nusinersen therapy were included in the study. The nutritional status of these patients was assessed by using anthropometric measurements, including height for age (HFA), weight for height (WFH), and body mass index (BMI) before and after the study. Additionally, the risk of malnutrition was determined using screening tools, namely the Pediatric Yorkhill Malnutrition Score (PYMS) and the Screening Tool for the Assessment of Malnutrition in Pediatrics (STAMP). Nutritional counseling followed the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) guidelines and considered the patients' dietary history, including content and administration method. Motor functions were assessed by validated tests: the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) and the Hammersmith Functional Motor Scale-Expanded (HFMSE). Result The study showed an improvement in HFA, by a change from -0.95 to -0.65 (p = 0.015). Conversely, BMI scores decreased from 0.08 to -0.54 (p = 0.015), while WFH and MUAC showed no significant alterations (p = 0.135, p = 0.307). Following nutritional interventions, HFMSE demonstrated a median increase from 29.5 to 30.5 (p = 0.023). Patients identified as being at high risk for malnutrition based on PYMS and STAMP belonged to the moderate-to-severe malnutrition group (BMI Z-score <= -2, p = 0.001). Conclusions Use of screening tools in SMA patients is highly beneficial for the early detection of malnutrition. Future research should highlight the importance of combining nutritional management with nusinersen therapy to potentially alter the disease trajectory, especially in motor and neurological functions.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy
    Edinoff, Amber N.
    Nguyen, Long H.
    Odisho, Amira S.
    Maxey, Benjamin S.
    Pruitt, John W.
    Girma, Brook
    Cornett, Elyse M.
    Kaye, Adam M.
    Kaye, Alan D.
    ORTHOPEDIC REVIEWS, 2021, 13 (02)
  • [22] Respiratory requirements of children with Spinal Muscular Atrophy Type 1 receiving Nusinersen in Ireland.
    Butler, D.
    Hynes, M.
    Mernagh, A.
    O'Rourke, D.
    Healy, F.
    Williamson, M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2018, 187 : S277 - S277
  • [23] Intrathecal Nusinersen in Older Children and Adults with Spinal Muscular Atrophy
    Veerapandiyan, A.
    Eichinger, K.
    Guntrum, D.
    Kwon, J.
    Collins, E.
    Ciafaloni, E.
    ANNALS OF NEUROLOGY, 2019, 86 : S130 - S130
  • [24] Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment
    Scheijmans, F. E. V.
    Cuppen, I.
    Zwartkruis, M. M.
    Signoria, I.
    van Ekris, C.
    Asselman, F.
    Wadman, R. I.
    Knol, E. F.
    van der Pol, W. L.
    Groen, E. J. N.
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2023, 42 : 34 - 41
  • [25] Nusinersen (Spinraza) for Spinal Muscular Atrophy
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1517): : 50 - 52
  • [26] Intrathecal nusinersen in older children and adults with spinal muscular atrophy
    Veerapandiyan, Aravindhan
    Eichinger, Katy
    Guntrum, Debra
    Collins, Erin
    Kwon, Jennifer
    Ciafaloni, Emma
    NEUROLOGY, 2019, 92 (15)
  • [27] Children and young adults with spinal muscular atrophy treated with nusinersen
    Osredkar, Damjan
    Jilkova, Marketa
    Butenko, Tita
    Loboda, Tanja
    Golli, Tanja
    Fuchsova, Petra
    Rohlenova, Marie
    Haberlova, Jana
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2021, 30 : 1 - 8
  • [28] Nusinersen for adults with spinal muscular atrophy
    Arslan, Doruk
    Inan, Berin
    Kilinc, Muhammed
    Bekircan-Kurt, Can Ebru
    Erdem-Ozdamar, Sevim
    Tan, Ersin
    NEUROLOGICAL SCIENCES, 2023, 44 (07) : 2393 - 2400
  • [29] Nusinersen for adults with spinal muscular atrophy
    Doruk Arslan
    Berin Inan
    Muhammed Kilinc
    Can Ebru Bekircan-Kurt
    Sevim Erdem-Ozdamar
    Ersin Tan
    Neurological Sciences, 2023, 44 : 2393 - 2400
  • [30] Monitoring Nusinersen Treatment Effects in Children with Spinal Muscular Atrophy with Quantitative Muscle MRI
    Otto, Louise A. M.
    Froeling, M.
    van Eijk, Ruben P. A.
    Wadman, Renske I.
    Cuppen, Inge
    van der Woude, Danny R.
    Bartels, Bart
    Asselman, Fay-Lynn
    Hendrikse, Jeroen
    van der Pol, W. Ludo
    JOURNAL OF NEUROMUSCULAR DISEASES, 2024, 11 (01) : 91 - 101